Trinity Biotech plc ADS/$TRIB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Trinity Biotech plc ADS
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has three segments, namely the Americas, Asia/Africa, and Europe, from which it derives a majority of its revenue from the Americas segment.
Ticker
$TRIB
Sector
Primary listing
Employees
287
Headquarters
Bray, Ireland
Website
TRIB Metrics
BasicAdvanced
$7.6m
-
-$2.01
0.87
-
Price and volume
Market cap
$7.6m
Beta
0.87
52-week high
$3.44
52-week low
$0.31
Average daily volume
2.5m
Financial strength
Current ratio
0.254
Quick ratio
0.109
Long term debt to equity
-37.746
Total debt to equity
-191.691
Interest coverage (TTM)
-0.75%
Profitability
EBITDA (TTM)
-8.243
Gross margin (TTM)
38.57%
Net profit margin (TTM)
-85.36%
Operating margin (TTM)
-21.80%
Effective tax rate (TTM)
-0.54%
Revenue per employee (TTM)
$150,000
Management effectiveness
Return on assets (TTM)
-5.72%
Return on equity (TTM)
69.76%
Valuation
Price to revenue (TTM)
0.16
Price to book
-0.1
Price to tangible book (TTM)
-0.07
Price to free cash flow (TTM)
-0.576
Free cash flow yield (TTM)
-173.76%
Free cash flow per share (TTM)
-0.654
Growth
Revenue change (TTM)
-28.87%
Earnings per share change (TTM)
-0.98%
3-year revenue growth (CAGR)
-11.20%
10-year revenue growth (CAGR)
-7.94%
3-year earnings per share growth (CAGR)
-30.82%
10-year earnings per share growth (CAGR)
-1.37%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs